Quantum Biopharma (QNTM) EBT (2019 - 2026)

Quantum Biopharma has disclosed EBT across 8 years of filings, most recently posting -$2.4 million for Q2 2026.

• In Q2 2026, EBT rose 52.15% year-over-year to -$2.4 million; the TTM figure through Jun 2026 stood at -$12.4 million (up 100.0% YoY), while the FY2025 annual figure was -$15.5 million, up 4.38% from the prior year.
• EBT came in at -$2.4 million for Q2 2026 at Quantum Biopharma, up from -$3.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $5.6 million in Q1 2022 to a low of -$1544.8 billion in Q3 2023.
• Average EBT over 5 years is -$130.6 billion, with a median of -$4.1 million recorded in 2025.
• The largest YoY upside for EBT was 124.34% in 2023 against a maximum downside of 21247767.1% in 2023.
• Over 5 years, EBT stood at -$6.7 million in 2022, then surged by 124.34% to $1.6 million in 2023, then sank by 229.14% to -$2.1 million in 2024, then retreated by 9.91% to -$2.3 million in 2025, then fell by 3.36% to -$2.4 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$2.4 million in Q2 2026, -$3.0 million in Q1 2026, and -$2.3 million in Q4 2025.